XOMA Corporation (XOMAP) 10-Year Financial Performance & Capital Metrics

XOMAP • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutXOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Show more

Revenue $28M +498.7%
EBITDA -$40M +2.9%
Net Income -$14M +66.2%
EPS (Diluted) -1.65 +59.2%
Gross Margin 99.28% +2.4%
EBITDA Margin -139.57% +83.8%
Operating Margin -140.33% +84.0%
Net Margin -48.52% +94.3%
ROE -16.2% +57.8%
ROIC -37.63% +24.4%
Debt/Equity 1.46 +3.7%
Interest Coverage -2.89 +96.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.21%

5Y9.17%

3Y-9.28%

TTM118.02%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM172.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM163.25%

ROCE

10Y Avg-30.32%

5Y Avg-6%

3Y Avg-18.52%

Latest-19.42%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	55.45M	5.56M	52.69M	5.3M	18.37M	29.39M	38.16M	6.03M	4.76M	28.49M
Revenue Growth %	1.94%	-0.9%	8.47%	-0.9%	2.47%	0.6%	0.3%	-0.84%	-0.21%	4.99%
Cost of Goods Sold+	20.7M	1.4M	7.88M	1.68M	1.25M	170K	171K	274K	143K	206K
COGS % of Revenue	0.37%	0.25%	0.15%	0.32%	0.07%	0.01%	0%	0.05%	0.03%	0.01%
Gross Profit+	34.75M	4.16M	44.81M	3.62M	17.12M	29.21M	37.99M	5.75M	4.62M	28.28M
Gross Margin %	0.63%	0.75%	0.85%	0.68%	0.93%	0.99%	1%	0.95%	0.97%	0.99%
Gross Profit Growth %	4.28%	-0.88%	9.76%	-0.92%	3.73%	0.71%	0.3%	-0.85%	-0.2%	5.13%
Operating Expenses+	91.47M	62.56M	32.21M	20.25M	21M	16.8M	20.46M	23.17M	46.46M	68.26M
OpEx % of Revenue	1.65%	11.24%	0.61%	3.82%	1.14%	0.57%	0.54%	3.84%	9.77%	2.4%
Selling, General & Admin	20.62M	18.32M	24.34M	18.56M	21M	16.8M	20.46M	23.19M	27.18M	34.48M
SG&A % of Revenue	0.37%	3.29%	0.46%	3.5%	1.14%	0.57%	0.54%	3.85%	5.71%	1.21%
Research & Development	70.85M	44.23M	7.88M	1.68M	1.25M	170K	171K	153K	143K	2.88M
R&D % of Revenue	1.28%	7.95%	0.15%	0.32%	0.07%	0.01%	0%	0.03%	0.03%	0.1%
Other Operating Expenses	44K	1.51M	1.11M	4.34M	-1.25M	-170K	-171K	-177K	19.14M	30.9M
Operating Income+	-39.72M	-61.56M	17.03M	-16.86M	-3.88M	12.42M	17.53M	-17.41M	-41.85M	-39.98M
Operating Margin %	-0.72%	-11.06%	0.32%	-3.18%	-0.21%	0.42%	0.46%	-2.89%	-8.8%	-1.4%
Operating Income Growth %	0.51%	-0.55%	1.28%	-1.99%	0.77%	4.2%	0.41%	-1.99%	-1.4%	0.04%
EBITDA+	-38.19M	-60.79M	17.34M	-16.83M	-1.97M	12.59M	17.54M	-17.14M	-40.95M	-39.76M
EBITDA Margin %	-0.69%	-10.93%	0.33%	-3.18%	-0.11%	0.43%	0.46%	-2.84%	-8.61%	-1.4%
EBITDA Growth %	0.52%	-0.59%	1.29%	-1.97%	0.88%	7.39%	0.39%	-1.98%	-1.39%	0.03%
D&A (Non-Cash Add-back)	1.53M	769K	304K	30K	1.92M	172K	7K	274K	900K	216K
EBIT	-16.97M	-49.6M	17.49M	-12.56M	-63K	13.64M	17.53M	-17.12M	-23.46M	-5.64M
Net Interest Income+	-3.77M	-3.95M	-1.24M	-922K	-1.92M	-1.84M	-461K	694K	-569K	-13.84M
Interest Income	0	0	0	0	0	0	0	694K	0	0
Interest Expense	4.18M	3.95M	1.24M	922K	1.92M	1.84M	461K	0	569K	13.84M
Other Income/Expense	19.12M	8.03M	-773K	3.42M	1.9M	-619K	-1.64M	295K	1.02M	20.5M
Pretax Income+	-20.61M	-53.53M	16.26M	-13.44M	-1.98M	11.8M	15.89M	-17.12M	-40.83M	-19.48M
Pretax Margin %	-0.37%	-9.62%	0.31%	-2.54%	-0.11%	0.4%	0.42%	-2.84%	-8.58%	-0.68%
Income Tax+	0	0	1.66M	-98K	0	-1.5M	91K	-15K	0	-5.66M
Effective Tax Rate %	1%	1%	0.9%	0.99%	1%	1.13%	0.99%	1%	1%	0.71%
Net Income+	-20.61M	-53.53M	14.6M	-13.34M	-1.98M	13.3M	15.8M	-17.1M	-40.83M	-13.82M
Net Margin %	-0.37%	-9.62%	0.28%	-2.52%	-0.11%	0.45%	0.41%	-2.84%	-8.58%	-0.49%
Net Income Growth %	0.46%	-1.6%	1.27%	-1.91%	0.85%	7.71%	0.19%	-2.08%	-1.39%	0.66%
Net Income (Continuing)	-20.61M	-53.53M	14.6M	-13.34M	-1.98M	13.3M	15.8M	-17.1M	-40.83M	-13.82M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.82	-4.72	0.73	-1.18	-0.88	0.78	0.65	-1.98	-4.04	-1.65
EPS Growth %	0.46%	-1.59%	1.15%	-2.62%	0.25%	1.89%	-0.17%	-4.05%	-1.04%	0.59%
EPS (Basic)	-1.82	-4.72	0.75	-1.18	-0.88	0.82	0.69	-1.98	-4.04	-1.65
Diluted Shares Outstanding	11.33M	11.33M	11.33M	11.33M	8.76M	11.5M	12.19M	11.41M	11.47M	11.7M
Basic Shares Outstanding	11.33M	11.33M	11.33M	11.33M	8.76M	10.67M	11.29M	11.41M	11.47M	11.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	72.22M	27.16M	44.2M	47.63M	59.97M	88.06M	96.97M	61.25M	169.31M	125.6M
Cash & Short-Term Investments	66.26M	25.74M	43.47M	45.78M	56.69M	84.22M	94.1M	58.16M	153.45M	105.18M
Cash Only	65.77M	25.74M	43.47M	45.78M	56.69M	84.22M	93.33M	57.83M	153.29M	101.65M
Short-Term Investments	496K	0	0	0	0	0	774K	335K	161K	3.53M
Accounts Receivable	4.07M	566K	397K	1.47M	2.93M	1.79M	209K	2.37M	15.22M	17.02M
Days Sales Outstanding	26.79	37.13	2.75	101.12	58.28	22.22	2	143.35	1.17K	218.01
Inventory	0	0	0	0	0	1.61M	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	3.46K	-	-	-	-
Other Current Assets	0	852K	327K	0	0	0	2.05M	725K	160K	1.33M
Total Non-Current Assets+	2.66M	1.52M	740K	16.16M	35.75M	37.22M	69.59M	79.13M	64.99M	95.67M
Property, Plant & Equipment	2M	1.04M	83K	59K	544K	380K	213K	36K	403K	351K
Fixed Asset Turnover	27.77x	5.37x	634.82x	89.81x	33.77x	77.33x	179.15x	167.42x	11.81x	81.16x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	15.15M	0	25.91M
Long-Term Investments	0	0	0	392K	681K	1.69M	0	63.68M	64.05M	0
Other Non-Current Assets	664K	481K	657K	15.71M	34.53M	35.15M	69.38M	63.94M	533K	69.41M
Total Assets+	74.88M	28.68M	44.94M	63.78M	95.72M	125.28M	166.56M	140.38M	234.3M	221.28M
Asset Turnover	0.74x	0.19x	1.17x	0.08x	0.19x	0.23x	0.23x	0.04x	0.02x	0.13x
Asset Growth %	-0.16%	-0.62%	0.57%	0.42%	0.5%	0.31%	0.33%	-0.16%	0.67%	-0.06%
Total Current Liabilities+	23.3M	32.51M	7.42M	5.7M	8.88M	12.3M	12.97M	6.82M	19.5M	24.37M
Accounts Payable	6.83M	5.69M	1.68M	1.24M	614K	456K	1.07M	524K	653K	1.05M
Days Payables Outstanding	120.45	1.48K	77.82	269.95	178.86	979.06	2.29K	698.03	1.67K	1.87K
Short-Term Debt	5.91M	17.86M	0	789K	5.18M	8.09M	0	0	5.54M	11.39M
Deferred Revenue (Current)	1000K	899K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	3.49M	1.79M	1.99M	2.08M	132K	1.56M	8.13M	2.35M	9.78M	3M
Current Ratio	3.10x	0.84x	5.95x	8.35x	6.76x	7.16x	7.48x	8.98x	8.68x	5.15x
Quick Ratio	3.10x	0.84x	5.95x	8.35x	6.76x	7.03x	7.48x	8.98x	8.68x	5.15x
Cash Conversion Cycle	-	-	-	-	-	2.5K	-	-	-	-
Total Non-Current Liabilities+	53.89M	43.38M	31.73M	39.3M	42.86M	26.56M	11.72M	9.55M	126.08M	114.98M
Long-Term Debt	42.76M	25.31M	14.57M	21.69M	27.09M	12.76M	0	0	118.52M	106.88M
Capital Lease Obligations	0	69K	0	0	408K	229K	34K	0	335K	483K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.14M	0	32K	590K	43K	50K	0	0	0	3.21M
Total Liabilities	77.19M	75.89M	39.15M	45M	51.74M	38.86M	24.69M	16.37M	145.58M	139.36M
Total Debt+	48.67M	43.17M	14.57M	22.48M	32.85M	21.26M	229K	34K	124.45M	119.2M
Net Debt	-17.1M	17.43M	-28.9M	-23.3M	-23.84M	-62.96M	-93.1M	-57.79M	-28.84M	17.54M
Debt / Equity	-	-	2.52x	1.20x	0.75x	0.25x	0.00x	0.00x	1.40x	1.46x
Debt / EBITDA	-	-	0.84x	-	-	1.69x	0.01x	-	-	-
Net Debt / EBITDA	-	-	-1.67x	-	-	-5.00x	-5.31x	-	-	-
Interest Coverage	-9.50x	-15.60x	13.76x	-18.28x	-2.02x	6.73x	38.02x	-	-73.55x	-2.89x
Total Equity+	-2.31M	-47.21M	5.79M	18.79M	43.99M	86.42M	141.88M	124.01M	88.72M	81.92M
Equity Growth %	-1.75%	-19.45%	1.12%	2.25%	1.34%	0.96%	0.64%	-0.13%	-0.28%	-0.08%
Book Value per Share	-0.20	-4.17	0.51	1.66	5.02	7.51	11.64	10.87	7.73	7.00
Total Shareholders' Equity	-2.31M	-47.21M	5.79M	18.79M	43.99M	86.42M	141.88M	124.01M	88.72M	81.92M
Common Stock	893K	46K	62K	65K	73K	84K	85K	86K	86K	90K
Retained Earnings	-1.14B	-1.19B	-1.18B	-1.19B	-1.19B	-1.18B	-1.17B	-1.18B	-1.22B	-1.24B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-15.45M	-13.54M	-41K	0	0	0	0	0	0	73K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-30.89M	-33.69M	2.69M	-12.64M	-285K	10.09M	22.68M	-12.88M	-18.16M	-13.75M
Operating CF Margin %	-0.56%	-6.05%	0.05%	-2.39%	-0.02%	0.34%	0.59%	-2.14%	-3.82%	-0.48%
Operating CF Growth %	0.61%	-0.09%	1.08%	-5.71%	0.98%	36.41%	1.25%	-1.57%	-0.41%	0.24%
Net Income	-20.61M	-53.53M	14.6M	-13.34M	-1.98M	13.3M	15.8M	-17.1M	-40.83M	-13.82M
Depreciation & Amortization	1.53M	769K	304K	30K	25K	22K	7K	104K	934K	216K
Stock-Based Compensation	9.73M	7.64M	7.3M	3.9M	4.95M	3.96M	6.2M	3.61M	9.22M	10.31M
Deferred Taxes	-21.78M	-9.92M	1.72M	0	-187K	0	0	0	0	-5.66M
Other Non-Cash Items	1.41M	1.56M	-13.04M	-251K	1.01M	-7.38M	1.56M	694K	13.41M	-2.01M
Working Capital Changes	-1.17M	19.79M	-8.2M	-2.98M	-4.09M	187K	-886K	-181K	-898K	-2.79M
Change in Receivables	-761K	3.53M	169K	-1.03M	-1.56M	1.14M	1.58M	208K	-1M	-835K
Change in Inventory	0	0	0	0	1.56M	0	0	0	0	0
Change in Payables	-1.62M	-3.94M	-6.55M	-1.16M	-242K	-542K	765K	1.84M	0	1.6M
Cash from Investing+	4.45M	612K	1.61M	-15.01M	-19.3M	-209K	-26.5M	-20.22M	-711K	-28.26M
Capital Expenditures	-430K	-59K	-8K	-15.01M	-19.3M	-9K	-26.5M	-15.25M	-17K	-20K
CapEx % of Revenue	0.01%	0.01%	0%	2.83%	1.05%	0%	0.69%	2.53%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	18K	49K	1.61M	-15M	0	-200K	0	-4.97M	-694K	-23.75M
Cash from Financing+	13.8M	-6.94M	13.26M	29.94M	30.49M	19.79M	12.84M	-4.45M	120.59M	-11.13M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-3.5M	-5.47M	-5.47M	-5.47M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-201K	0	-490K	120K	-54K	506K	-19.42M	1.02M	-3.79M	1.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.32M	-33.75M	2.68M	-27.65M	-19.59M	8.88M	-3.82M	-28.13M	-18.18M	-13.77M
FCF Margin %	-0.56%	-6.07%	0.05%	-5.22%	-1.07%	0.3%	-0.1%	-4.67%	-3.82%	-0.48%
FCF Growth %	0.6%	-0.08%	1.08%	-11.32%	0.29%	1.45%	-1.43%	-6.36%	0.35%	0.24%
FCF per Share	-2.76	-2.98	0.24	-2.44	-2.23	0.77	-0.31	-2.46	-1.58	-1.18
FCF Conversion (FCF/Net Income)	1.50x	0.63x	0.18x	0.95x	0.14x	0.76x	1.44x	0.75x	0.44x	0.99x
Interest Paid	0	0	0	81K	0	692K	311K	0	0	9.98M
Taxes Paid	0	0	0	1.64M	0	0	0	76K	0	9.98M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-5216.71%	-	252.26%	-108.61%	-6.31%	20.39%	13.84%	-12.87%	-38.39%	-16.2%
Return on Invested Capital (ROIC)	-	-	-	-	-37.28%	42.71%	36.4%	-22.71%	-49.78%	-37.63%
Gross Margin	62.67%	74.84%	85.05%	68.26%	93.18%	99.42%	99.55%	95.45%	96.99%	99.28%
Net Margin	-37.16%	-962.08%	27.7%	-251.8%	-10.79%	45.25%	41.4%	-283.79%	-858.15%	-48.52%
Debt / Equity	-	-	2.52x	1.20x	0.75x	0.25x	0.00x	0.00x	1.40x	1.46x
Interest Coverage	-9.50x	-15.60x	13.76x	-18.28x	-2.02x	6.73x	38.02x	-	-73.55x	-2.89x
FCF Conversion	1.50x	0.63x	0.18x	0.95x	0.14x	0.76x	1.44x	0.75x	0.44x	0.99x
Revenue Growth	193.9%	-89.97%	846.98%	-89.94%	246.67%	59.96%	29.86%	-84.21%	-21.06%	498.72%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
SWITZERLAND	-	-	-	-	-	-	-	-	-	14.8M
SWITZERLAND Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	3.82M	1.65M	3.94M	-	-	-	-	3.66M	12.06M
UNITED STATES Growth	-	-	-56.72%	137.91%	-	-	-	-	-	229.74%
Asia Pacific	100K	100K	100K	350K	600K	3.1M	550K	1.55M	1.1M	1.13M
Asia Pacific Growth	-	0.00%	0.00%	250.00%	71.43%	416.67%	-82.26%	181.82%	-29.03%	2.27%
Europe	44.66M	1.64M	50.94M	1.01M	100K	25.01M	35M	-	-	500K
Europe Growth	-	-96.32%	3002.07%	-98.01%	-90.14%	24910.00%	39.94%	-	-	-
United States	-	-	-	-	-	-	2.61M	4.48M	-	-
United States Growth	-	-	-	-	-	-	-	71.53%	-	-
U S	10.69M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

XOMA Corporation (XOMAP) reported $47.1M in revenue for fiscal year 2024. This represents a 19% decrease from $58.2M in 2011.

XOMA Corporation (XOMAP) grew revenue by 498.7% over the past year. This is strong growth.

Yes, XOMA Corporation (XOMAP) is profitable, generating $21.7M in net income for fiscal year 2024 (-48.5% net margin).

Dividend & Returns

Yes, XOMA Corporation (XOMAP) pays a dividend with a yield of 1.79%. This makes it attractive for income-focused investors.

XOMA Corporation (XOMAP) has a return on equity (ROE) of -16.2%. Negative ROE indicates the company is unprofitable.

XOMA Corporation (XOMAP) generated $5.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

XOMA Corporation (XOMAP) 10-Year Financial Performance & Capital Metrics

XOMAP • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $28M +498.7%
EBITDA -$40M +2.9%
Net Income -$14M +66.2%
EPS (Diluted) -1.65 +59.2%
Gross Margin 99.28% +2.4%
EBITDA Margin -139.57% +83.8%
Operating Margin -140.33% +84.0%
Net Margin -48.52% +94.3%
ROE -16.2% +57.8%
ROIC -37.63% +24.4%
Debt/Equity 1.46 +3.7%
Interest Coverage -2.89 +96.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.21%

5Y9.17%

3Y-9.28%

TTM118.02%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM172.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM163.25%

ROCE

10Y Avg-30.32%

5Y Avg-6%

3Y Avg-18.52%

Latest-19.42%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	55.45M	5.56M	52.69M	5.3M	18.37M	29.39M	38.16M	6.03M	4.76M	28.49M
Revenue Growth %	1.94%	-0.9%	8.47%	-0.9%	2.47%	0.6%	0.3%	-0.84%	-0.21%	4.99%
Cost of Goods Sold+	20.7M	1.4M	7.88M	1.68M	1.25M	170K	171K	274K	143K	206K
COGS % of Revenue	0.37%	0.25%	0.15%	0.32%	0.07%	0.01%	0%	0.05%	0.03%	0.01%
Gross Profit+	34.75M	4.16M	44.81M	3.62M	17.12M	29.21M	37.99M	5.75M	4.62M	28.28M
Gross Margin %	0.63%	0.75%	0.85%	0.68%	0.93%	0.99%	1%	0.95%	0.97%	0.99%
Gross Profit Growth %	4.28%	-0.88%	9.76%	-0.92%	3.73%	0.71%	0.3%	-0.85%	-0.2%	5.13%
Operating Expenses+	91.47M	62.56M	32.21M	20.25M	21M	16.8M	20.46M	23.17M	46.46M	68.26M
OpEx % of Revenue	1.65%	11.24%	0.61%	3.82%	1.14%	0.57%	0.54%	3.84%	9.77%	2.4%
Selling, General & Admin	20.62M	18.32M	24.34M	18.56M	21M	16.8M	20.46M	23.19M	27.18M	34.48M
SG&A % of Revenue	0.37%	3.29%	0.46%	3.5%	1.14%	0.57%	0.54%	3.85%	5.71%	1.21%
Research & Development	70.85M	44.23M	7.88M	1.68M	1.25M	170K	171K	153K	143K	2.88M
R&D % of Revenue	1.28%	7.95%	0.15%	0.32%	0.07%	0.01%	0%	0.03%	0.03%	0.1%
Other Operating Expenses	44K	1.51M	1.11M	4.34M	-1.25M	-170K	-171K	-177K	19.14M	30.9M
Operating Income+	-39.72M	-61.56M	17.03M	-16.86M	-3.88M	12.42M	17.53M	-17.41M	-41.85M	-39.98M
Operating Margin %	-0.72%	-11.06%	0.32%	-3.18%	-0.21%	0.42%	0.46%	-2.89%	-8.8%	-1.4%
Operating Income Growth %	0.51%	-0.55%	1.28%	-1.99%	0.77%	4.2%	0.41%	-1.99%	-1.4%	0.04%
EBITDA+	-38.19M	-60.79M	17.34M	-16.83M	-1.97M	12.59M	17.54M	-17.14M	-40.95M	-39.76M
EBITDA Margin %	-0.69%	-10.93%	0.33%	-3.18%	-0.11%	0.43%	0.46%	-2.84%	-8.61%	-1.4%
EBITDA Growth %	0.52%	-0.59%	1.29%	-1.97%	0.88%	7.39%	0.39%	-1.98%	-1.39%	0.03%
D&A (Non-Cash Add-back)	1.53M	769K	304K	30K	1.92M	172K	7K	274K	900K	216K
EBIT	-16.97M	-49.6M	17.49M	-12.56M	-63K	13.64M	17.53M	-17.12M	-23.46M	-5.64M
Net Interest Income+	-3.77M	-3.95M	-1.24M	-922K	-1.92M	-1.84M	-461K	694K	-569K	-13.84M
Interest Income	0	0	0	0	0	0	0	694K	0	0
Interest Expense	4.18M	3.95M	1.24M	922K	1.92M	1.84M	461K	0	569K	13.84M
Other Income/Expense	19.12M	8.03M	-773K	3.42M	1.9M	-619K	-1.64M	295K	1.02M	20.5M
Pretax Income+	-20.61M	-53.53M	16.26M	-13.44M	-1.98M	11.8M	15.89M	-17.12M	-40.83M	-19.48M
Pretax Margin %	-0.37%	-9.62%	0.31%	-2.54%	-0.11%	0.4%	0.42%	-2.84%	-8.58%	-0.68%
Income Tax+	0	0	1.66M	-98K	0	-1.5M	91K	-15K	0	-5.66M
Effective Tax Rate %	1%	1%	0.9%	0.99%	1%	1.13%	0.99%	1%	1%	0.71%
Net Income+	-20.61M	-53.53M	14.6M	-13.34M	-1.98M	13.3M	15.8M	-17.1M	-40.83M	-13.82M
Net Margin %	-0.37%	-9.62%	0.28%	-2.52%	-0.11%	0.45%	0.41%	-2.84%	-8.58%	-0.49%
Net Income Growth %	0.46%	-1.6%	1.27%	-1.91%	0.85%	7.71%	0.19%	-2.08%	-1.39%	0.66%
Net Income (Continuing)	-20.61M	-53.53M	14.6M	-13.34M	-1.98M	13.3M	15.8M	-17.1M	-40.83M	-13.82M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.82	-4.72	0.73	-1.18	-0.88	0.78	0.65	-1.98	-4.04	-1.65
EPS Growth %	0.46%	-1.59%	1.15%	-2.62%	0.25%	1.89%	-0.17%	-4.05%	-1.04%	0.59%
EPS (Basic)	-1.82	-4.72	0.75	-1.18	-0.88	0.82	0.69	-1.98	-4.04	-1.65
Diluted Shares Outstanding	11.33M	11.33M	11.33M	11.33M	8.76M	11.5M	12.19M	11.41M	11.47M	11.7M
Basic Shares Outstanding	11.33M	11.33M	11.33M	11.33M	8.76M	10.67M	11.29M	11.41M	11.47M	11.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	72.22M	27.16M	44.2M	47.63M	59.97M	88.06M	96.97M	61.25M	169.31M	125.6M
Cash & Short-Term Investments	66.26M	25.74M	43.47M	45.78M	56.69M	84.22M	94.1M	58.16M	153.45M	105.18M
Cash Only	65.77M	25.74M	43.47M	45.78M	56.69M	84.22M	93.33M	57.83M	153.29M	101.65M
Short-Term Investments	496K	0	0	0	0	0	774K	335K	161K	3.53M
Accounts Receivable	4.07M	566K	397K	1.47M	2.93M	1.79M	209K	2.37M	15.22M	17.02M
Days Sales Outstanding	26.79	37.13	2.75	101.12	58.28	22.22	2	143.35	1.17K	218.01
Inventory	0	0	0	0	0	1.61M	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	3.46K	-	-	-	-
Other Current Assets	0	852K	327K	0	0	0	2.05M	725K	160K	1.33M
Total Non-Current Assets+	2.66M	1.52M	740K	16.16M	35.75M	37.22M	69.59M	79.13M	64.99M	95.67M
Property, Plant & Equipment	2M	1.04M	83K	59K	544K	380K	213K	36K	403K	351K
Fixed Asset Turnover	27.77x	5.37x	634.82x	89.81x	33.77x	77.33x	179.15x	167.42x	11.81x	81.16x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	15.15M	0	25.91M
Long-Term Investments	0	0	0	392K	681K	1.69M	0	63.68M	64.05M	0
Other Non-Current Assets	664K	481K	657K	15.71M	34.53M	35.15M	69.38M	63.94M	533K	69.41M
Total Assets+	74.88M	28.68M	44.94M	63.78M	95.72M	125.28M	166.56M	140.38M	234.3M	221.28M
Asset Turnover	0.74x	0.19x	1.17x	0.08x	0.19x	0.23x	0.23x	0.04x	0.02x	0.13x
Asset Growth %	-0.16%	-0.62%	0.57%	0.42%	0.5%	0.31%	0.33%	-0.16%	0.67%	-0.06%
Total Current Liabilities+	23.3M	32.51M	7.42M	5.7M	8.88M	12.3M	12.97M	6.82M	19.5M	24.37M
Accounts Payable	6.83M	5.69M	1.68M	1.24M	614K	456K	1.07M	524K	653K	1.05M
Days Payables Outstanding	120.45	1.48K	77.82	269.95	178.86	979.06	2.29K	698.03	1.67K	1.87K
Short-Term Debt	5.91M	17.86M	0	789K	5.18M	8.09M	0	0	5.54M	11.39M
Deferred Revenue (Current)	1000K	899K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	3.49M	1.79M	1.99M	2.08M	132K	1.56M	8.13M	2.35M	9.78M	3M
Current Ratio	3.10x	0.84x	5.95x	8.35x	6.76x	7.16x	7.48x	8.98x	8.68x	5.15x
Quick Ratio	3.10x	0.84x	5.95x	8.35x	6.76x	7.03x	7.48x	8.98x	8.68x	5.15x
Cash Conversion Cycle	-	-	-	-	-	2.5K	-	-	-	-
Total Non-Current Liabilities+	53.89M	43.38M	31.73M	39.3M	42.86M	26.56M	11.72M	9.55M	126.08M	114.98M
Long-Term Debt	42.76M	25.31M	14.57M	21.69M	27.09M	12.76M	0	0	118.52M	106.88M
Capital Lease Obligations	0	69K	0	0	408K	229K	34K	0	335K	483K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	11.14M	0	32K	590K	43K	50K	0	0	0	3.21M
Total Liabilities	77.19M	75.89M	39.15M	45M	51.74M	38.86M	24.69M	16.37M	145.58M	139.36M
Total Debt+	48.67M	43.17M	14.57M	22.48M	32.85M	21.26M	229K	34K	124.45M	119.2M
Net Debt	-17.1M	17.43M	-28.9M	-23.3M	-23.84M	-62.96M	-93.1M	-57.79M	-28.84M	17.54M
Debt / Equity	-	-	2.52x	1.20x	0.75x	0.25x	0.00x	0.00x	1.40x	1.46x
Debt / EBITDA	-	-	0.84x	-	-	1.69x	0.01x	-	-	-
Net Debt / EBITDA	-	-	-1.67x	-	-	-5.00x	-5.31x	-	-	-
Interest Coverage	-9.50x	-15.60x	13.76x	-18.28x	-2.02x	6.73x	38.02x	-	-73.55x	-2.89x
Total Equity+	-2.31M	-47.21M	5.79M	18.79M	43.99M	86.42M	141.88M	124.01M	88.72M	81.92M
Equity Growth %	-1.75%	-19.45%	1.12%	2.25%	1.34%	0.96%	0.64%	-0.13%	-0.28%	-0.08%
Book Value per Share	-0.20	-4.17	0.51	1.66	5.02	7.51	11.64	10.87	7.73	7.00
Total Shareholders' Equity	-2.31M	-47.21M	5.79M	18.79M	43.99M	86.42M	141.88M	124.01M	88.72M	81.92M
Common Stock	893K	46K	62K	65K	73K	84K	85K	86K	86K	90K
Retained Earnings	-1.14B	-1.19B	-1.18B	-1.19B	-1.19B	-1.18B	-1.17B	-1.18B	-1.22B	-1.24B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-15.45M	-13.54M	-41K	0	0	0	0	0	0	73K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-30.89M	-33.69M	2.69M	-12.64M	-285K	10.09M	22.68M	-12.88M	-18.16M	-13.75M
Operating CF Margin %	-0.56%	-6.05%	0.05%	-2.39%	-0.02%	0.34%	0.59%	-2.14%	-3.82%	-0.48%
Operating CF Growth %	0.61%	-0.09%	1.08%	-5.71%	0.98%	36.41%	1.25%	-1.57%	-0.41%	0.24%
Net Income	-20.61M	-53.53M	14.6M	-13.34M	-1.98M	13.3M	15.8M	-17.1M	-40.83M	-13.82M
Depreciation & Amortization	1.53M	769K	304K	30K	25K	22K	7K	104K	934K	216K
Stock-Based Compensation	9.73M	7.64M	7.3M	3.9M	4.95M	3.96M	6.2M	3.61M	9.22M	10.31M
Deferred Taxes	-21.78M	-9.92M	1.72M	0	-187K	0	0	0	0	-5.66M
Other Non-Cash Items	1.41M	1.56M	-13.04M	-251K	1.01M	-7.38M	1.56M	694K	13.41M	-2.01M
Working Capital Changes	-1.17M	19.79M	-8.2M	-2.98M	-4.09M	187K	-886K	-181K	-898K	-2.79M
Change in Receivables	-761K	3.53M	169K	-1.03M	-1.56M	1.14M	1.58M	208K	-1M	-835K
Change in Inventory	0	0	0	0	1.56M	0	0	0	0	0
Change in Payables	-1.62M	-3.94M	-6.55M	-1.16M	-242K	-542K	765K	1.84M	0	1.6M
Cash from Investing+	4.45M	612K	1.61M	-15.01M	-19.3M	-209K	-26.5M	-20.22M	-711K	-28.26M
Capital Expenditures	-430K	-59K	-8K	-15.01M	-19.3M	-9K	-26.5M	-15.25M	-17K	-20K
CapEx % of Revenue	0.01%	0.01%	0%	2.83%	1.05%	0%	0.69%	2.53%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	18K	49K	1.61M	-15M	0	-200K	0	-4.97M	-694K	-23.75M
Cash from Financing+	13.8M	-6.94M	13.26M	29.94M	30.49M	19.79M	12.84M	-4.45M	120.59M	-11.13M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-3.5M	-5.47M	-5.47M	-5.47M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-201K	0	-490K	120K	-54K	506K	-19.42M	1.02M	-3.79M	1.26M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.32M	-33.75M	2.68M	-27.65M	-19.59M	8.88M	-3.82M	-28.13M	-18.18M	-13.77M
FCF Margin %	-0.56%	-6.07%	0.05%	-5.22%	-1.07%	0.3%	-0.1%	-4.67%	-3.82%	-0.48%
FCF Growth %	0.6%	-0.08%	1.08%	-11.32%	0.29%	1.45%	-1.43%	-6.36%	0.35%	0.24%
FCF per Share	-2.76	-2.98	0.24	-2.44	-2.23	0.77	-0.31	-2.46	-1.58	-1.18
FCF Conversion (FCF/Net Income)	1.50x	0.63x	0.18x	0.95x	0.14x	0.76x	1.44x	0.75x	0.44x	0.99x
Interest Paid	0	0	0	81K	0	692K	311K	0	0	9.98M
Taxes Paid	0	0	0	1.64M	0	0	0	76K	0	9.98M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-5216.71%	-	252.26%	-108.61%	-6.31%	20.39%	13.84%	-12.87%	-38.39%	-16.2%
Return on Invested Capital (ROIC)	-	-	-	-	-37.28%	42.71%	36.4%	-22.71%	-49.78%	-37.63%
Gross Margin	62.67%	74.84%	85.05%	68.26%	93.18%	99.42%	99.55%	95.45%	96.99%	99.28%
Net Margin	-37.16%	-962.08%	27.7%	-251.8%	-10.79%	45.25%	41.4%	-283.79%	-858.15%	-48.52%
Debt / Equity	-	-	2.52x	1.20x	0.75x	0.25x	0.00x	0.00x	1.40x	1.46x
Interest Coverage	-9.50x	-15.60x	13.76x	-18.28x	-2.02x	6.73x	38.02x	-	-73.55x	-2.89x
FCF Conversion	1.50x	0.63x	0.18x	0.95x	0.14x	0.76x	1.44x	0.75x	0.44x	0.99x
Revenue Growth	193.9%	-89.97%	846.98%	-89.94%	246.67%	59.96%	29.86%	-84.21%	-21.06%	498.72%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
SWITZERLAND	-	-	-	-	-	-	-	-	-	14.8M
SWITZERLAND Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	-	3.82M	1.65M	3.94M	-	-	-	-	3.66M	12.06M
UNITED STATES Growth	-	-	-56.72%	137.91%	-	-	-	-	-	229.74%
Asia Pacific	100K	100K	100K	350K	600K	3.1M	550K	1.55M	1.1M	1.13M
Asia Pacific Growth	-	0.00%	0.00%	250.00%	71.43%	416.67%	-82.26%	181.82%	-29.03%	2.27%
Europe	44.66M	1.64M	50.94M	1.01M	100K	25.01M	35M	-	-	500K
Europe Growth	-	-96.32%	3002.07%	-98.01%	-90.14%	24910.00%	39.94%	-	-	-
United States	-	-	-	-	-	-	2.61M	4.48M	-	-
United States Growth	-	-	-	-	-	-	-	71.53%	-	-
U S	10.69M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

XOMA Corporation (XOMAP) reported $47.1M in revenue for fiscal year 2024. This represents a 19% decrease from $58.2M in 2011.

XOMA Corporation (XOMAP) grew revenue by 498.7% over the past year. This is strong growth.

Yes, XOMA Corporation (XOMAP) is profitable, generating $21.7M in net income for fiscal year 2024 (-48.5% net margin).

Dividend & Returns

Yes, XOMA Corporation (XOMAP) pays a dividend with a yield of 1.79%. This makes it attractive for income-focused investors.

XOMA Corporation (XOMAP) has a return on equity (ROE) of -16.2%. Negative ROE indicates the company is unprofitable.

XOMA Corporation (XOMAP) generated $5.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.